Search results
Added:
10 months ago
Source:
Radcliffe Cardiology
The decision to switch frail, elderly patients with atrial fibrillation (AF) from a stable vitamin K antagonist (VKA) regimen to a direct-acting oral anticoagulant (DOAC) remains a subject of clinical debate. A new substudy from the COMBINE-AF dataset provides clarity, suggesting that while the switch reduces severe outcomes like stroke and death, it does not lower the risk of major bleeding and…
View more
Added:
2 months ago
ACC.26 - At ACC.26 in New Orleans, Dr Devi Nair (Arkansas, US) and Dr Vivek Reddy (New York, US) dissect the late-breaking CHAMPION‑AF trial, a large randomized comparison of first-line left atrial appendage closure with WATCHMAN FLX versus continued NOAC therapy in patients with non-valvular AF who can tolerate anticoagulation. They review the trial design, post‑implant antithrombotic and…
View more
Added:
1 year ago
AF Symposium 25 - Left atrial appendage (LAA) closure using the WATCHMAN FLX device (Boston Scientific) showed lower risk of bleeding and non-inferiority in efficacy endpoints to oral anticoagulation in patients who have received or are planning to receive AF ablation.Dr Walid Saliba (Cleveland Clinic, OH, US) joins us onsite at AF Symposium 25 to discuss the findings from the concomitant and…
View more
Device-detected AF: How Much is Too Much?
Added:
1 month ago
Expert Opinion
AF Symposium 2025 Late-Breaking Science Collection
Video Series
Added:
1 month ago
In this expert discussion, DrKarim Al-Azizi(Baylor Scott & White The Heart Hospital, US), Editor-in-Chief of the Transcatheter Academy, is joined by steering committee members DrDevi Nair(Chief VP of Research, Arkansas Heart Hospital, US) and DrMegan Coylewright(Essentia Health, US) to unpack the landmark CHAMPION-AF trial (NCT05964200) and its implications for stroke prevention in atrial…
View more
Added:
2 months ago
ACC.26 – Late-breaker host Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Saibal Kar, MD (Los Robles Regional Medical Center, US) to discuss CHAMPION‑AF (NCT04394546), a global randomized trial comparing the WATCHMAN FLX left atrial appendage closure device with non–vitamin K oral anticoagulants in patients with non‑valvular atrial fibrillation at elevated stroke risk…
View more
Added:
9 months ago
Source:
Arrhythmia Academy
Managing antithrombotic therapy in older patients with both atrial fibrillation (AF) and stable coronary artery disease (CAD) presents a clinical challenge, balancing the risks of thrombotic events and bleeding. A new post hoc analysis of the AFIRE trial sought to clarify whether the effects of rivaroxaban monotherapy differ across age groups compared to combination therapy with an antiplatelet…
View more
Added:
1 year ago
ESC Congress 24 — AF screening with a wearable ECG device increases diagnosis by over 50% but did not significantly reduce hospitalisation rates for stroke.We are joined onsite at ESC Congress 2024 by Dr Renato Lopes (Duke University Medical Center, NC) to discuss the findings from the GUARD-AF Trial (NCT04126486, Bristol-Myers Squibb), which was designed to determine if screening for undiagnosed…
View more
Sunil V Rao
Job title: MD, Assistant Professor of Medicine
Author